These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25379062)

  • 1. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
    Moses RG; Colagiuri S; Pollock C
    Australas Med J; 2014; 7(10):405-15. PubMed ID: 25379062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes.
    Peene B; Benhalima K
    Ther Adv Endocrinol Metab; 2014 Oct; 5(5):124-36. PubMed ID: 25419452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose Control and Cardiovascular Outcomes in Clinical Trials of Sodium Glucose Co-transporter 2 Inhibitor Treatments in Type 2 Diabetes.
    A Oliveros R; V Pham S; R Bailey S; J Chilton R
    Eur Endocrinol; 2014 Aug; 10(2):117-123. PubMed ID: 29872475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States.
    Neslusan C; Teschemaker A; Willis M; Johansen P; Vo L
    Diabetes Ther; 2018 Apr; 9(2):565-581. PubMed ID: 29411292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin.
    Seufert J
    Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.
    Demin O; Yakovleva T; Kolobkov D; Demin O
    Front Pharmacol; 2014; 5():218. PubMed ID: 25352807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin in patients with type 2 diabetes mellitus.
    Filippatos TD; Liberopoulos EN; Elisaf MS
    Ther Adv Endocrinol Metab; 2015 Feb; 6(1):29-41. PubMed ID: 25678954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
    Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
    Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes.
    Mikhail N
    World J Diabetes; 2014 Dec; 5(6):854-9. PubMed ID: 25512787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
    Brunton S; Reid TS
    Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renal effects of SGLT2 inhibitors and a mini-review of the literature.
    Andrianesis V; Glykofridi S; Doupis J
    Ther Adv Endocrinol Metab; 2016 Dec; 7(5-6):212-228. PubMed ID: 28203358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks Associated with SGLT2 Inhibitors: An Overview.
    Singh M; Kumar A
    Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments in type 2 diabetes: focus on canagliflozin.
    Rosiak M; Grzeszczak S; Kosior DA; Postuła M
    Ther Clin Risk Manag; 2014; 10():683-9. PubMed ID: 25187722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.